TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) shares crossed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.87 and traded as high as $0.9399. TriSalus Life Sciences shares last traded at $0.9420, with a volume of 1,810 shares traded.
TriSalus Life Sciences Price Performance
The stock’s 50-day moving average price is $0.87 and its 200-day moving average price is $0.97.
Institutional Investors Weigh In On TriSalus Life Sciences
A hedge fund recently bought a new stake in TriSalus Life Sciences stock. State Street Corp bought a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 610,963 shares of the company’s stock, valued at approximately $2,780,000.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences is a medical technology and therapeutics company focused on improving treatment delivery for patients with solid tumors, particularly tumors in the liver and pancreas. Its approach combines proprietary drug-delivery technology with the development of immunotherapies.
The company’s TriNav® infusion system is designed to deliver therapies into tumors using its Pressure-Enabled Drug Delivery (PEDD) approach. TriSalus is also developing investigational therapies intended to work alongside its delivery platform; these therapies are not established treatments.
TriSalus became a publicly traded company in 2023 through a business combination with MedTech Acquisition Corporation.
See Also
- Five stocks we like better than TriSalus Life Sciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
